Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Part of paid clinical trials in Detroit, Michigan.

Sponsor
Bindu R Potugari
Study ID
NCT07339059
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)
  • Small Cell Lung Cancer ( SCLC )

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sacituzumab govitecan — DRUG
    Sacituzumab govitecan 10 mg/kg via IV infusion on Day 1 and Day 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment)
  • Atezolizumab — DRUG
    Atezolizumab 1200mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks)
  • Durvalumab — DRUG
    Durvalumab 1500mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks)

Study Details

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient. * CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks. * provide tissue (optional) and blood for additional testing (learn about the cancer).

Key Dates

Start date
Jun 1, 2026
Status verified
Jan 2026
Primary completion
Feb 1, 2029
Completion
Dec 1, 2029

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SG and atezolizumab/durvalumab
    Sacituzumab govitecan 10 mg/kg via IV infusion on Day 1 and Day 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) AND Atezolizumab 1200mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks) OR Sacituzumab govitecan 10 mg/kg via IV infusion on Day 1 and Day 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) AND Durvalumab 1500mg via IV infusion on Day 1 of a 21-day cycle (ie, once every 3 weeks)

Primary Outcome Measure

Disease Control [ Time Frame: 12 weeks from study enrollment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Henry Ford Cancer- DetroitDetroitMichigan48202
Bethany Adams, RN
[email protected]
313.556.8107

Find similar trials in Detroit, MI

By research site
Henry Ford Cancer- Detroit· Detroit, MI

Related Studies